GO:0110023 negative regulation of cardiac muscle myoblast proliferation: Regulatory Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0110023 describes any process that stops, prevents, or reduces the frequency, rate or extent of cardiac muscle myoblast proliferation [QuickGO definition].
• Cardiac muscle myoblasts are proliferative progenitors that withdraw from the cell cycle before differentiating into cardiomyocytes, making this negative regulation essential for proper heart development.
• MicroRNAs such as miR-1, miR-133, and miR-34a are well-established post-transcriptional regulators of cardiac and skeletal myoblast proliferation and differentiation.
• Signaling pathways including TGF-beta/Smad3 and adenylate cyclase/cAMP modulate the balance between myoblast proliferation and differentiation.
• Dysregulation of this process is linked to cardiotoxicity, impaired cardiac regeneration, and neuromuscular disorders.
• CRISPR-based knockout, knock-in, and overexpression models enable causal dissection of genes controlling cardiac myoblast proliferation arrest.
Description
The Gene Ontology term GO:0110023, negative regulation of cardiac muscle myoblast proliferation, defines any process that stops, prevents, or reduces the frequency, rate or extent of cardiac muscle myoblast proliferation [QuickGO]. Cardiac muscle myoblasts are embryonic progenitor cells committed to the cardiomyocyte lineage; they must proliferate to expand the pool of precursor cells and then exit the cell cycle to differentiate into functional cardiomyocytes. Understanding how this proliferation arrest is controlled is fundamental to developmental biology and to strategies for cardiac regeneration. This GO term is critical for researchers because the timing and extent of cardiac myoblast proliferation directly influence heart size, chamber formation, and postnatal cardiac function. Perturbations in the negative regulation of cardiac myoblast proliferation can lead to congenital heart defects, cardiotoxicity, or failed regeneration after injury. Moreover, the same regulatory molecules, such as microRNAs and TGF-beta/Smad3 signaling components, are often conserved between skeletal and cardiac muscle, offering cross-tissue insights. In practice, GO:0110023 is used to annotate gene products that experimentally reduce cardiac myoblast proliferation, including microRNAs, transcription factors, and signaling pathway components. Researchers leverage this term to interpret transcriptomic and functional genomics data, to prioritize candidate genes for CRISPR screens, and to build mechanistic models of cardiac development and disease.
negative regulation of cardiac muscle myoblast proliferation At A Glance
| GO ID | GO:0110023 |
|---|---|
| GO term | negative regulation of cardiac muscle myoblast proliferation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Stops or reduces the proliferation of cardiac muscle myoblasts, often preceding differentiation into cardiomyocytes |
| Related processes | Cardiac muscle myoblast proliferation, cardiac muscle cell differentiation, cell cycle arrest |
| Key regulators | MicroRNAs (e.g., miR-1, miR-133, miR-34a), TGF-beta/Smad3 signaling, adenylate cyclase/cAMP pathway |
| Disease relevance | Cardiotoxicity, impaired cardiac regeneration, neuromuscular disorders |
| Experimental models | H9c2 cardiomyoblasts, P19CL6 cells, primary cardiac myoblasts, CRISPR-engineered cell lines |
What Is GO:0110023?
In our own words, GO:0110023 refers to any biological process that decreases the rate, frequency, or extent of proliferation of cardiac muscle myoblasts, which are the proliferating precursor cells of cardiac muscle. This regulation can occur through cell-cycle arrest, reduced mitogenic signaling, or increased differentiation cues, and it is essential for normal heart development [QuickGO].
Why Is negative regulation of cardiac muscle myoblast proliferation Important in Cell Biology?
GO:0110023 is important because the negative regulation of cardiac muscle myoblast proliferation is a decisive step in heart development and regeneration. When this process is disrupted, excessive or insufficient proliferation can lead to malformed hearts, cardiotoxicity, or failure to regenerate after injury. Understanding the molecular players that enforce proliferation arrest provides targets for regenerative medicine and for protecting the heart from damage.
• Controls the size of the cardiac myoblast pool before differentiation, affecting heart morphogenesis.
• Prevents uncontrolled proliferation that could lead to cardiac hyperplasia or tumors.
• Is essential for the transition from proliferating myoblasts to differentiated cardiomyocytes.
• Dysregulation is associated with doxorubicin-induced cardiotoxicity.
• Implicated in neuromuscular disorders where satellite cell dysfunction occurs.
• Provides a framework for understanding microRNA-mediated regulation of cardiac development.
• Offers targets for promoting cardiac regeneration after injury.
• Helps interpret gene expression changes in cardiac differentiation models such as H9c2 and P19CL6.
• Guides CRISPR screening for regulators of cardiac myoblast proliferation arrest.
• Connects to conserved mechanisms in skeletal muscle regeneration.
What Happens During negative regulation of cardiac muscle myoblast proliferation?
Initiation of proliferation arrest
In simple terms: The cell receives signals to stop dividing.
Negative regulation of cardiac muscle myoblast proliferation begins when extracellular or intracellular cues activate pathways that inhibit cell-cycle progression. For example, activation of the adenylate cyclase system in H9c2 cardiomyoblasts can reduce proliferation and promote differentiation. Similarly, microRNAs such as miR-1 and miR-133 are induced during cardiac development and repress factors that drive proliferation.
Cell cycle exit and differentiation commitment
In simple terms: The cell permanently leaves the cell cycle and starts becoming a heart muscle cell.
Once proliferation is inhibited, cardiac myoblasts exit the cell cycle and commit to differentiation. This transition involves downregulation of cyclins and CDKs, and upregulation of differentiation markers. In P19CL6 cells, Id1 induces differentiation and proliferation, but negative regulators like APOBEC2 can block differentiation in skeletal muscle, highlighting the balance between proliferation and differentiation. In cardiac cells, TGF-beta/Smad3 signaling promotes differentiation while inhibiting proliferation.
MicroRNA-mediated post-transcriptional control
In simple terms: Small RNA molecules fine-tune the levels of proteins that control cell division.
MicroRNAs are key negative regulators of cardiac myoblast proliferation. miR-1 and miR-133 are muscle-specific microRNAs that modulate proliferation and differentiation. miR-34a regulates doxorubicin-induced cardiotoxicity and can influence cardiac cell proliferation and survival. These microRNAs typically bind to the 3' UTR of target mRNAs, reducing their translation or stability, thereby reducing proliferative signaling.
Signaling pathways that enforce proliferation arrest
In simple terms: Communication pathways inside the cell act as brakes on cell division.
The TGF-beta/Smad3 pathway is a well-known negative regulator of myoblast proliferation; knockdown of CSRP3 promotes TGF-beta/Smad3 signaling and inhibits differentiation of chicken satellite cells. In cardiac muscle, similar pathways may enforce proliferation arrest. Additionally, the adenylate cyclase/cAMP pathway can inhibit proliferation of H9c2 cardiomyoblasts. These pathways converge on cell-cycle regulators to stop proliferation.
Integration with cardiac muscle development
In simple terms: The stopping of cell division is coordinated with the overall plan of heart formation.
Negative regulation of cardiac muscle myoblast proliferation is integrated with cardiac morphogenesis. Proper timing ensures that the heart has enough cells but does not overgrow. Disruption of this process can lead to congenital heart defects or impaired cardiac function. MicroRNAs and signaling pathways coordinate this integration, and their dysregulation is linked to cardiotoxicity and neuromuscular disorders.
Key Genes Involved in GO:0110023 negative regulation of cardiac muscle myoblast proliferation
The following genes and non-coding RNAs have been experimentally implicated in the negative regulation of cardiac muscle myoblast proliferation or related processes in cardiac and skeletal muscle models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MIR1-1 | Muscle-specific microRNA that inhibits proliferation and promotes differentiation | Key regulator of cardiac and skeletal myoblast proliferation |
| MIR133A1 | Muscle-specific microRNA that modulates proliferation and differentiation | Regulates cardiac myoblast proliferation and differentiation |
| MIR34A | MicroRNA involved in cardiotoxicity and cell cycle regulation | Regulates doxorubicin-induced cardiotoxicity and cardiac cell proliferation |
| CSRP3 | Cysteine-rich protein 3, modulates TGF-beta/Smad3 signaling | Knockdown promotes TGF-beta/Smad3 and inhibits differentiation; relevant to proliferation arrest |
| APOBEC2 | Negative regulator of myoblast differentiation | Negatively regulates differentiation in muscle regeneration; may influence proliferation |
| ID1 | Inhibitor of DNA binding 1, induces differentiation and proliferation | Regulates proliferation and differentiation in P19CL6 cells |
| ADCY | Adenylate cyclase, produces cAMP | Modulates differentiation of H9c2 cardiomyoblasts; affects proliferation |
| SMAD3 | TGF-beta signaling effector | Promotes differentiation and inhibits proliferation in myoblasts |
| TGFB1 | Transforming growth factor beta 1 | Activates Smad3 to inhibit myoblast proliferation |
| CDKN1A | Cyclin-dependent kinase inhibitor 1A (p21) | Potential mediator of cell cycle arrest in cardiac myoblasts |
| CDKN1B | Cyclin-dependent kinase inhibitor 1B (p27) | Potential mediator of cell cycle arrest |
| MYOD1 | Myogenic differentiation factor | Promotes differentiation and may indirectly inhibit proliferation |
| MYOG | Myogenin, differentiation marker | Indicates differentiation commitment after proliferation arrest |
| MEF2C | Myocyte enhancer factor 2C | Transcription factor involved in cardiac differentiation |
| GATA4 | Cardiac transcription factor | Regulates cardiac gene expression and development |
| NKX2-5 | Cardiac transcription factor | Essential for heart development and cardiomyocyte differentiation |
| TBX5 | T-box transcription factor | Involved in cardiac development and proliferation control |
| HAND2 | Heart and neural crest derivatives expressed 2 | Regulates cardiac morphogenesis and differentiation |
How Is negative regulation of cardiac muscle myoblast proliferation Regulated?
The negative regulation of cardiac muscle myoblast proliferation is controlled by a network of microRNAs, signaling pathways, and transcription factors. MicroRNAs such as miR-1, miR-133, and miR-34a post-transcriptionally repress proliferative genes. The TGF-beta/Smad3 pathway inhibits proliferation while promoting differentiation, and its activity can be modulated by CSRP3. The adenylate cyclase/cAMP pathway also influences the balance between proliferation and differentiation in H9c2 cardiomyoblasts. Additionally, Id1 and APOBEC2 have been shown to regulate differentiation and proliferation in muscle contexts. These regulators ensure timely cell cycle exit during cardiac development.
negative regulation of cardiac muscle myoblast proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MIR34A | Doxorubicin-induced cardiotoxicity | Rat cardiomyocytes, H9c2 cells |
| CSRP3 | Muscle differentiation disorders | Chicken satellite cells, C2C12 |
| APOBEC2 | Muscle regeneration defects | Mouse myoblasts, C2C12 |
| ID1 | Cardiac differentiation and proliferation | P19CL6 cells |
| ADCY | Cardiac hypertrophy and differentiation | H9c2 cardiomyoblasts |
Cardiotoxicity and heart failure
Dysregulation of cardiac myoblast proliferation and its negative regulation can contribute to cardiotoxicity. miR-34a regulates doxorubicin-induced cardiotoxicity in rats, and its modulation affects cardiac cell survival and function. Impaired proliferation arrest may lead to failed regeneration or maladaptive remodeling after injury, highlighting the importance of this process in heart failure.
Neuromuscular disorders
Muscle satellite cell dysfunction is a hallmark of neuromuscular disorders, and mechanisms controlling proliferation and differentiation are often shared between skeletal and cardiac muscle. Genes such as APOBEC2 and CSRP3 regulate myoblast differentiation and proliferation, and their dysregulation may contribute to muscle-wasting conditions.
Congenital heart defects
Proper negative regulation of cardiac muscle myoblast proliferation is essential for normal heart development. Disruption of microRNA networks or signaling pathways that enforce proliferation arrest can lead to congenital heart defects and abnormal cardiac morphogenesis.
From negative regulation of cardiac muscle myoblast proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate cardiac myoblast proliferation? | CRISPR knockout in H9c2 or primary cardiac myoblasts, followed by proliferation assays |
| Does a point mutation in gene X affect its function in proliferation arrest? | CRISPR point mutation knock-in in H9c2 cells |
| Does overexpression of gene X inhibit proliferation? | CRISPR overexpression (e.g., CRISPRa) or lentiviral overexpression in P19CL6 cells |
| Does a tagged version of gene X localize correctly and interact with partners? | CRISPR knock-in of epitope tag in cardiac myoblasts |
| Which microRNAs regulate cardiac myoblast proliferation? | MicroRNA mimics/inhibitors in H9c2 cells, RNA-seq |
| Does TGF-beta/Smad3 signaling mediate proliferation arrest? | CRISPR knockout of SMAD3 in myoblasts, TGF-beta treatment |
How to Study the negative regulation of cardiac muscle myoblast proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| EdU/BrdU incorporation | DNA synthesis and proliferation rate | Assess proliferation after gene knockout or overexpression |
| RNA-seq | Global gene expression changes | Identify pathways and microRNA targets |
| MicroRNA mimic/inhibitor transfection | Effect of microRNA on proliferation | Validate miR-1, miR-133, miR-34a function |
| Western blot | Protein expression and signaling activation | Measure TGF-beta/Smad3, cell cycle regulators |
| Immunofluorescence | Localization of proteins and proliferation markers | Detect Ki-67, myosin heavy chain |
| CRISPR knockout | Loss-of-function phenotype | Test candidate negative regulators |
| CRISPR activation (CRISPRa) | Gain-of-function phenotype | Overexpress candidate genes |
| Luciferase reporter assay | MicroRNA target validation | Confirm direct binding of microRNAs to 3' UTR |
Proliferation assays
EdU incorporation, BrdU labeling, and Ki-67 staining are standard methods to measure cardiac myoblast proliferation. These assays can be applied to H9c2 cells or primary cardiac myoblasts after genetic manipulation.
Transcriptomic analysis
RNA-seq can identify global changes in gene expression upon negative regulation of proliferation. This is useful for discovering microRNA targets and signaling pathways, as shown in studies of miR-1, miR-133, and miR-34a.
MicroRNA functional studies
Transfection of microRNA mimics or inhibitors followed by proliferation and differentiation assays can establish the role of specific microRNAs in cardiac myoblast proliferation arrest.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify novel regulators of cardiac myoblast proliferation. These screens are powerful for uncovering genes that negatively regulate proliferation when knocked out or overexpressed.
How CRISPR Can Be Used to Study GO:0110023 negative regulation of cardiac muscle myoblast proliferation
Knockout
CRISPR knockout of candidate genes in cardiac myoblast models such as H9c2 or P19CL6 can determine whether the gene is required for negative regulation of proliferation. For example, knocking out SMAD3 would test its role in TGF-beta-mediated proliferation arrest. Knockout of microRNA genes can also be achieved to assess their function.
Point Mutation
CRISPR point mutation knock-in allows precise modification of genes to mimic disease-associated variants or to abrogate specific phosphorylation sites. This is useful for studying how post-translational modifications affect the negative regulation of cardiac myoblast proliferation.
Knock-in
Knock-in of reporter genes (e.g., fluorescent proteins) or epitope tags enables live-cell imaging and biochemical analysis of proteins involved in proliferation arrest. For instance, tagging a cell cycle inhibitor can reveal its dynamics during differentiation.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can force expression of candidate negative regulators to test whether they are sufficient to stop cardiac myoblast proliferation. This approach is valuable for microRNAs and transcription factors.
How EDITGENE Supports negative regulation of cardiac muscle myoblast proliferation Research
Researchers studying negative regulation of cardiac muscle myoblast proliferation-related genes often need to determine whether a candidate gene is causally involved in this process. EDITGENE provides comprehensive CRISPR-based services to enable such functional studies in cardiac cell models.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cardiac muscle myoblast proliferation research.
Frequently Asked Questions About negative regulation of cardiac muscle myoblast proliferation
What is GO:0110023?
GO:0110023 is the Gene Ontology term for negative regulation of cardiac muscle myoblast proliferation, defined as any process that stops, prevents, or reduces the frequency, rate or extent of cardiac muscle myoblast proliferation [QuickGO].
What genes are involved in negative regulation of cardiac muscle myoblast proliferation?
Key genes include microRNAs such as MIR1-1, MIR133A1, and MIR34A, as well as signaling components like CSRP3, SMAD3, and APOBEC2.
How do microRNAs regulate cardiac myoblast proliferation?
MicroRNAs such as miR-1 and miR-133 post-transcriptionally repress target mRNAs that promote proliferation, thereby reducing proliferation and promoting differentiation.
What is the role of TGF-beta/Smad3 signaling in cardiac myoblast proliferation?
TGF-beta/Smad3 signaling inhibits myoblast proliferation and promotes differentiation; CSRP3 knockdown enhances this pathway.
Which cell models are used to study cardiac myoblast proliferation?
Common models include H9c2 cardiomyoblasts and P19CL6 cells, which can be differentiated and manipulated genetically.
How is cardiac muscle myoblast proliferation measured?
Proliferation is typically measured by EdU or BrdU incorporation, Ki-67 staining, and cell counting assays.
What diseases are linked to dysregulation of cardiac myoblast proliferation?
Dysregulation is linked to cardiotoxicity, congenital heart defects, and neuromuscular disorders.
Can CRISPR be used to study negative regulation of cardiac myoblast proliferation?
Yes, CRISPR knockout, knock-in, and activation can be used to test the function of candidate genes in cardiac myoblast models.
What is the difference between cardiac muscle myoblast proliferation and differentiation?
Proliferation is cell division, while differentiation is the process of becoming a specialized cardiomyocyte; negative regulation of proliferation often precedes differentiation.
How does miR-34a affect cardiac cells?
miR-34a regulates doxorubicin-induced cardiotoxicity and can influence cardiac cell proliferation and survival.
Conclusion
GO:0110023, negative regulation of cardiac muscle myoblast proliferation, is a critical biological process that ensures proper heart development by stopping progenitor cell division at the right time. MicroRNAs, signaling pathways, and transcription factors coordinate this arrest, and their dysregulation contributes to cardiotoxicity, congenital heart defects, and muscle disorders. Understanding these mechanisms offers opportunities for regenerative medicine and therapeutic intervention. Researchers can leverage CRISPR-based models to dissect the causal roles of specific genes in this process. EDITGENE provides end-to-end services to accelerate such discoveries.
References
- 1. Ganassi M et al.. 2022. Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.. Eur J Transl Myol 32(1) PMID: 35302338
- 2. Callis TE et al.. 2007. MicroRNAs in skeletal and cardiac muscle development.. DNA Cell Biol 26(4):219-25 PMID: 17465888
- 3. van Rooij E et al.. 2008. MicroRNAs flex their muscles.. Trends Genet 24(4):159-66 PMID: 18325627
- 4. Ohtsubo H et al.. 2017. APOBEC2 negatively regulates myoblast differentiation in muscle regeneration.. Int J Biochem Cell Biol 85:91-101 PMID: 28215905
- 5. Piegari E et al.. 2016. MicroRNA-34a regulates doxorubicin-induced cardiotoxicity in rat.. Oncotarget 7(38):62312-62326 PMID: 27694688
- 6. Han S et al.. 2019. Knockdown of CSRP3 inhibits differentiation of chicken satellite cells by promoting TGF-β/Smad3 signaling.. Gene 707:36-43 PMID: 30930226
- 7. Pagano M et al.. 2004. Differentiation of H9c2 cardiomyoblasts: The role of adenylate cyclase system.. J Cell Physiol 198(3):408-16 PMID: 14755546
- 8. Meng Q et al.. 2011. Inhibitor of DNA binding 1 (Id1) induces differentiation and proliferation of mouse embryonic carcinoma P19CL6 cells.. Biochem Biophys Res Commun 412(2):253-9 PMID: 21820417
